Navan Technologies specializes in innovative solutions for cell and gene therapies, focusing on their proprietary NanoStraw technology. This platform enables a non-perturbative and gentle delivery mechanism that allows for the transport of various cargo types, including DNA, mRNA, and proteins, into a wide range of primary cell types. The NanoStraws create a direct physical connection to cells, significantly reducing the challenges associated with traditional methods such as viral-based and electroporation techniques. This technology not only enhances cell viability and recovery but also streamlines the manufacturing process by minimizing technical difficulties and costs.

The capabilities of NanoStraw technology extend to precise dosage control, which is crucial for effective therapy development. This system is scalable, accommodating small numbers of cells for rare types as well as large-scale applications involving millions of cells. By addressing the viability and manufacturing hurdles that have historically hindered the progress of cell and gene therapies, Navan Technologies is positioned to advance therapeutic innovations across a broad spectrum of medical indications in collaboration with strategic partners.

United States

NAVAN Technologies, Inc. is an enabling technology company commercializing a novel non-viral delivery platform to radically accelerate genetic engineering of human stem & primary cells. The patented NanoStraw technology provides direct intracellular access into hard-to-transfect stem & primary human cells for efficacious delivery of any cargo. By using a physical, non-perturbative mechanism for delivery, the challenges of viral-based cell manufacturing (time, cost and technical difficulties) are eliminated, resulting in fewer, faster operational steps.

For more information on NAVAN, please visit www.navanbio.com.

Navan Technologies

Company Details